The 22nd China International Exhibition on Laboratory Medicine and Blood Transfusion Instruments and Reagents (CACLP) will be held from March 22nd to 24th, 2025 at the Hangzhou Convention and Exhibition Center. As the largest and most influential industry event in the field of IVD in Asia, this exhibition brings together top companies from around the world to explore the future of innovative laboratory medicine.
Zhejiang Longyue Biotechnology Co., Ltd. made a heavyweight debut with its HPV E7 protein detection reagent product, with the theme of "Precision Screening and Technology Empowerment", providing a new solution for early diagnosis and treatment of cervical cancer!
Exhibition Direct: Longyue Biotechnology's booth is extremely popular
At booth E0702 in Hall 8, Longyue Biotechnology launched exclusive national products and created an immersive interactive exhibition area, attracting numerous industry experts, distributors, and representatives of medical institutions to stop and exchange ideas.
The HPV E7 protein detection reagent independently developed by Longyue Biotechnology has become the focus of the exhibition. This technology directly detects HPV oncogenic protein E7 through immunohistochemistry, breaking through the bottleneck of traditional screening and possessing the following advantages:
1. Accuracy: Strong specificity, directly targeting carcinogenic factors, avoiding transient infection interference;
2. Convenience: Compatible with TCT samples, non-invasive testing, fast results within 3 hours;
3. Economy: Single testing replaces multi-step processes, reducing hospital costs.
Technical Experience Area: Viewers can operate the fully automated immunohistochemistry staining system on-site and experience the efficient screening process.
Zhejiang Longyue Biotechnology Co., Ltd. held a product promotion event on the afternoon of March 22 at the Wanyi Hotel in Hangzhou, providing a detailed introduction to the HPV E7 protein antibody reagent product. Mr. Wang Pinqing, Regional Sales Director of Longyue Biotechnology, delivered a welcome speech, and Sun Yujing, Product Manager of the Marketing Department, gave a presentation.
The project introduction is over. Professor Pan Jianping, doctoral supervisor at Zhejiang University and chief scientist of Longyue Biotechnology, gave a clear and concise explanation and supplement on the advantages of HPV E7 protein testing. Mr. Luo Fuquan, chairman of Longyue Biotechnology, shared forward-looking and strategic guidance on the product with everyone.
Looking to the future: Technology safeguards women's health
Technology is the boat, precision is the rudder.
Longyue Biotech leverages innovation to support global cervical cancer prevention and control efforts!
